Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.65
ACOR's Cash to Debt is ranked higher than
62% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ACOR: 2.65 )
ACOR' s 10-Year Cash to Debt Range
Min: 1.25   Max: No Debt
Current: 2.65

Equity to Asset 0.54
ACOR's Equity to Asset is ranked higher than
66% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ACOR: 0.54 )
ACOR' s 10-Year Equity to Asset Range
Min: -3.98   Max: 0.75
Current: 0.54

-3.98
0.75
Interest Coverage 13.99
ACOR's Interest Coverage is ranked higher than
51% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACOR: 13.99 )
ACOR' s 10-Year Interest Coverage Range
Min: 9.82   Max: 13.99
Current: 13.99

9.82
13.99
F-Score: 5
Z-Score: 3.32
M-Score: -3.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.75
ACOR's Operating margin (%) is ranked higher than
89% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. ACOR: 12.75 )
ACOR' s 10-Year Operating margin (%) Range
Min: -9345.93   Max: 12
Current: 12.75

-9345.93
12
Net-margin (%) 6.26
ACOR's Net-margin (%) is ranked higher than
86% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. ACOR: 6.26 )
ACOR' s 10-Year Net-margin (%) Range
Min: -9340.5   Max: 50.67
Current: 6.26

-9340.5
50.67
ROE (%) 5.03
ACOR's ROE (%) is ranked higher than
89% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. ACOR: 5.03 )
ACOR' s 10-Year ROE (%) Range
Min: -92.5   Max: 52.43
Current: 5.03

-92.5
52.43
ROA (%) 3.16
ACOR's ROA (%) is ranked higher than
89% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. ACOR: 3.16 )
ACOR' s 10-Year ROA (%) Range
Min: -109.5   Max: 32.8
Current: 3.16

-109.5
32.8
ROC (Joel Greenblatt) (%) 260.69
ACOR's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. ACOR: 260.69 )
ACOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3833.78   Max: 992.89
Current: 260.69

-3833.78
992.89
Revenue Growth (%) 17.50
ACOR's Revenue Growth (%) is ranked higher than
90% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ACOR: 17.50 )
ACOR' s 10-Year Revenue Growth (%) Range
Min: -61.8   Max: 73.6
Current: 17.5

-61.8
73.6
» ACOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ACOR Guru Trades in Q4 2013

Jim Simons 250,400 sh (New)
David Dreman 1,025 sh (New)
Paul Tudor Jones 17,000 sh (+120.78%)
Steven Cohen 44,981 sh (-47.03%)
» More
Q1 2014

ACOR Guru Trades in Q1 2014

Steven Cohen 370,900 sh (+724.57%)
David Dreman 1,526 sh (+48.88%)
Paul Tudor Jones Sold Out
Jim Simons 217,561 sh (-13.11%)
» More
Q2 2014

ACOR Guru Trades in Q2 2014

Joel Greenblatt 51,262 sh (New)
Steven Cohen 615,600 sh (unchged)
David Dreman Sold Out
Jim Simons 41,500 sh (-80.92%)
» More
Q3 2014

ACOR Guru Trades in Q3 2014

Joel Greenblatt 150,609 sh (+193.8%)
Jim Simons 97,900 sh (+135.9%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 193.8%0.03%$28.45 - $37.62 $ 38.4723%150609
Joel Greenblatt 2014-06-30 New Buy0.02%$29.69 - $38.89 $ 38.4713%51262
David Dreman 2014-06-30 Sold Out $29.69 - $38.89 $ 38.4713%0
David Dreman 2014-03-31 Add 48.88%$27.88 - $39.43 $ 38.4715%1526
David Dreman 2013-12-31 New Buy$28.89 - $36.54 $ 38.4718%1025
Joel Greenblatt 2012-12-31 Sold Out 0.02%$22.48 - $26.93 $ 38.4756%0
Joel Greenblatt 2012-06-30 New Buy0.02%$21.61 - $27.02 $ 38.4762%9329
John Burbank 2012-03-31 Sold Out 0.21%$24.85 - $27.49 $ 38.4759%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 68.80
ACOR's P/E(ttm) is ranked higher than
90% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 68.80 )
ACOR' s 10-Year P/E(ttm) Range
Min: 6.35   Max: 161.37
Current: 68.8

6.35
161.37
P/B 3.10
ACOR's P/B is ranked higher than
83% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. ACOR: 3.10 )
ACOR' s 10-Year P/B Range
Min: 2.33   Max: 44.88
Current: 3.1

2.33
44.88
P/S 4.30
ACOR's P/S is ranked higher than
90% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. ACOR: 4.30 )
ACOR' s 10-Year P/S Range
Min: 0.16   Max: 24.53
Current: 4.3

0.16
24.53
PFCF 21.40
ACOR's PFCF is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 21.40 )
ACOR' s 10-Year PFCF Range
Min: 10.97   Max: 130.85
Current: 21.4

10.97
130.85
EV-to-EBIT 23.94
ACOR's EV-to-EBIT is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 23.94 )
ACOR' s 10-Year EV-to-EBIT Range
Min: -99.3   Max: 93.5
Current: 23.94

-99.3
93.5
Shiller P/E 110.20
ACOR's Shiller P/E is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 110.20 )
ACOR' s 10-Year Shiller P/E Range
Min: 85.71   Max: 479.88
Current: 110.2

85.71
479.88
Current Ratio 8.36
ACOR's Current Ratio is ranked higher than
84% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. ACOR: 8.36 )
ACOR' s 10-Year Current Ratio Range
Min: 0.59   Max: 8.36
Current: 8.36

0.59
8.36
Quick Ratio 8.09
ACOR's Quick Ratio is ranked higher than
84% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ACOR: 8.09 )
ACOR' s 10-Year Quick Ratio Range
Min: 0.42   Max: 8.09
Current: 8.09

0.42
8.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.10
ACOR's Price/Net Cash is ranked higher than
89% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. ACOR: 5.10 )
ACOR' s 10-Year Price/Net Cash Range
Min: 4.51   Max: 67.12
Current: 5.1

4.51
67.12
Price/Net Current Asset Value 4.60
ACOR's Price/Net Current Asset Value is ranked higher than
89% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. ACOR: 4.60 )
ACOR' s 10-Year Price/Net Current Asset Value Range
Min: 4.27   Max: 46.21
Current: 4.6

4.27
46.21
Price/Tangible Book 3.20
ACOR's Price/Tangible Book is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. ACOR: 3.20 )
ACOR' s 10-Year Price/Tangible Book Range
Min: 2.63   Max: 129.47
Current: 3.2

2.63
129.47
Price/DCF (Projected) 1.90
ACOR's Price/DCF (Projected) is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 1.90 )
ACOR' s 10-Year Price/DCF (Projected) Range
Min: 1.76   Max: 22.28
Current: 1.9

1.76
22.28
Price/Median PS Value 0.90
ACOR's Price/Median PS Value is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ACOR: 0.90 )
ACOR' s 10-Year Price/Median PS Value Range
Min: 0.05   Max: 4.65
Current: 0.9

0.05
4.65
Price/Graham Number 3.10
ACOR's Price/Graham Number is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 3.10 )
ACOR' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 5.74
Current: 3.1

0.86
5.74
Earnings Yield (Greenblatt) 4.20
ACOR's Earnings Yield (Greenblatt) is ranked higher than
94% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ACOR: 4.20 )
ACOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 7.7
Current: 4.2

1.1
7.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CDG.Germany,
Acorda Therapeutics, Inc. was incorporated on March 17, 1995 as a Delaware corporation. It is a biopharmaceutical company, engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug approved by the FDA for the management of spasticity. The Company is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for "Fampyra" and "Kampyra" and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" and "Qutenza" in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.
» More Articles for ACOR

Headlines

Articles On GuruFocus.com
Fv 58 MSN 10 Apr 19 2013 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Acorda Therapeutics Inc. Reports Operating Results (10-K) Mar 01 2011 
Steve Cohen Buys ACOR, DPZ, GXDX, NDN, and OREX Feb 07 2011 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 15,000 Shares Dec 03 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 10,905 Shares Dec 03 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 55,000 Shares Aug 09 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 12,000 Shares Mar 12 2010 

More From Other Websites
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 15 2014
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking... Dec 15 2014
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking... Dec 15 2014
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 10 2014
Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson’s Disease Dec 10 2014
Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson’s Disease Dec 10 2014
Acorda Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference Dec 02 2014
Acorda Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference Dec 02 2014
Is Acorda Therapeutics (ACOR) Stock a Solid Choice Right Now? Dec 01 2014
ACORDA THERAPEUTICS INC Financials Nov 14 2014
Acorda Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference Nov 14 2014
Acorda Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference Nov 14 2014
Acorda Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference Nov 14 2014
Acorda Therapeutics to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
Acorda Therapeutics to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
10-Q for Acorda Therapeutics, Inc. Nov 09 2014
ACORDA THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
Acorda Therapeutics to Present at the Credit Suisse 2014 Healthcare Conference Nov 04 2014
Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook Oct 31 2014
Acorda tops 3Q revenue forecasts Oct 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK